Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data
January 15, 2019 | Peptalk
Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data
Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties
January 15, 2019 | Peptalk
Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties
(Sibeprenlimab), an APRIL-Neutralizing IgG2
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
(Sibeprenlimab), an APRIL-Neutralizing IgG2
Monoclonal Antibody, in Healthy Volunteers
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Monoclonal Antibody, in Healthy Volunteers
Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection
VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy
October 23, 2018 | American Society of Nephrology (ASN)
VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy
Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy
October 23, 2018 | American Society of Nephrology (ASN)
Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy
A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms
September 27, 2018 | International IgAN Symposium
A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms
Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys
September 27, 2018 | International IgAN Symposium
Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys
Developments in Computational-Based Methods for Antibody Design
September 27, 2018 | Discovery on target
